JPMDL To Mull Whether Eye Injury Cases Belong In Existing GLP-1 MDL
WASHINGTON, D.C. — The U.S. Judicial Panel on Multidistrict Litigation will hear arguments in December on whether cases alleging that the use of glucagon-like peptide-I receptor agonist (GLP-1 RA) medications caused...To view the full article, register now.
Already a subscriber? Click here to view full article